ATE101147T1 - Pharmazeutisch verwendbare polymorphe modifikation von buspiron. - Google Patents

Pharmazeutisch verwendbare polymorphe modifikation von buspiron.

Info

Publication number
ATE101147T1
ATE101147T1 AT88113970T AT88113970T ATE101147T1 AT E101147 T1 ATE101147 T1 AT E101147T1 AT 88113970 T AT88113970 T AT 88113970T AT 88113970 T AT88113970 T AT 88113970T AT E101147 T1 ATE101147 T1 AT E101147T1
Authority
AT
Austria
Prior art keywords
buspiron
pharmaceutically useable
polymorph modification
polymorph
modification
Prior art date
Application number
AT88113970T
Other languages
English (en)
Inventor
Jack C Simms
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22225222&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE101147(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Application granted granted Critical
Publication of ATE101147T1 publication Critical patent/ATE101147T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Anesthesiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Steroid Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Macromolecular Compounds Obtained By Forming Nitrogen-Containing Linkages In General (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Body Structure For Vehicles (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
AT88113970T 1987-08-28 1988-08-26 Pharmazeutisch verwendbare polymorphe modifikation von buspiron. ATE101147T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US07/090,984 US5015646A (en) 1987-08-28 1987-08-28 Pharmaceutically useful polymorphic modification of buspirone
EP88113970A EP0304941B1 (de) 1987-08-28 1988-08-26 Pharmazeutisch verwendbare polymorphe Modifikation von Buspiron

Publications (1)

Publication Number Publication Date
ATE101147T1 true ATE101147T1 (de) 1994-02-15

Family

ID=22225222

Family Applications (1)

Application Number Title Priority Date Filing Date
AT88113970T ATE101147T1 (de) 1987-08-28 1988-08-26 Pharmazeutisch verwendbare polymorphe modifikation von buspiron.

Country Status (22)

Country Link
US (1) US5015646A (de)
EP (1) EP0304941B1 (de)
JP (1) JP2716740B2 (de)
KR (1) KR970011297B1 (de)
AT (1) ATE101147T1 (de)
AU (1) AU618549B2 (de)
CY (1) CY1785A (de)
DE (1) DE3887598T2 (de)
DK (1) DK170821B1 (de)
ES (1) ES2061576T3 (de)
FI (1) FI883961A (de)
HK (1) HK74494A (de)
HU (1) HU201322B (de)
IE (1) IE63071B1 (de)
IL (1) IL87468A (de)
MY (1) MY104061A (de)
NO (1) NO883805D0 (de)
NZ (1) NZ225896A (de)
OA (1) OA08908A (de)
PT (1) PT88356B (de)
YU (1) YU46962B (de)
ZA (1) ZA886082B (de)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4810789A (en) * 1987-08-28 1989-03-07 Bristol-Myers Company Process for buspirone hydrochloride polymorphic crystalline form conversion
US5484788A (en) * 1993-03-26 1996-01-16 Beth Israel Hospital Association Buspirone as a systemic immunosuppressant
US5631017A (en) * 1993-03-26 1997-05-20 Beth Israel Deaconess Medical Center, Inc. Topical application of buspirone for treatment of pathological conditions associated with immune responses
HU217129B (hu) * 1993-07-16 1999-11-29 EGIS Gyógyszergyár Rt. Eljárás nagy tisztaságú buspiron gyógyászati hatóanyag előállítására
US5637314A (en) * 1995-06-07 1997-06-10 Beth Israel Deaconess Medical Center, Inc. Topical and systemic application of buspirone or derivatives thereof for treating atopic dermatitis
HU229405B1 (en) 1998-06-19 2013-12-30 Teijin Pharma Ltd Polymorphic modifications of 2-(3-cyano-4-isobutyloxyphenyl)-4-methyl-5-thiazolecarboxylic acid and processes for the preparation thereof
US6465255B1 (en) * 1999-01-29 2002-10-15 The Regents Of The University Of California Method for identifying and probing phase transitions in materials
KR100433165B1 (ko) * 2000-10-10 2004-05-27 엔앤비텍 주식회사 가공란의 제조 방법, 상기 방법에 의하여 제조된 가공란,및 가공란을 제조하기 위한 장치
CL2004001034A1 (es) 2003-05-14 2005-03-28 Teijin Pharma Ltd Formas cristalinas de acido 4-(1-((,etilbenzotiofen-3-il)me til)benzimidazol-2-iltio)butanoico; procedimiento de preparacion de las formas cristalinas; composicion farmaceutica; y su uso para el tratamiento de enfermedades inflamatorias, alergicas, r
WO2005107810A2 (en) 2004-05-11 2005-11-17 Emotional Brain B.V. Pharmaceutical formulations and uses thereof in the treatment of female sexual dysfunction
JPWO2006052026A1 (ja) * 2004-11-12 2008-05-29 帝人ファーマ株式会社 ベンズイミダゾール誘導体の酸性塩及びその結晶
EP1790343A1 (de) 2005-11-11 2007-05-30 Emotional Brain B.V. Pharmazeutische Zusammensetzungen und deren Verwendung zur Behandlung sexueller Störungen der Frau
EP1925307A1 (de) * 2006-11-03 2008-05-28 Emotional Brain B.V. Verwendung von 3-alpha-androstanediol zur Behandlung sexueller Dysfunktion

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE759371A (fr) * 1969-11-24 1971-05-24 Bristol Myers Co Azaspirodecanediones heterocycliques et procedes pour leur preparation
US3976776A (en) * 1972-12-06 1976-08-24 Mead Johnson & Company Tranquilizer process employing N-(heteroarcyclic)piperazinylalkylazaspiroalkanediones
US4351939A (en) * 1980-10-16 1982-09-28 Mead Johnson & Company Spiro-quaternary ammonium halides and N-(2-pyrimidinyl)piperazinylalkylazaspiroalkanedione process
US4476248A (en) * 1983-02-28 1984-10-09 The Upjohn Company Crystallization of ibuprofen

Also Published As

Publication number Publication date
IE63071B1 (en) 1995-03-22
NZ225896A (en) 1991-04-26
IL87468A0 (en) 1989-01-31
PT88356B (pt) 1995-03-31
US5015646A (en) 1991-05-14
JPS6471816A (en) 1989-03-16
DE3887598T2 (de) 1994-05-19
HU201322B (en) 1990-10-28
EP0304941A1 (de) 1989-03-01
PT88356A (pt) 1989-06-30
CY1785A (en) 1995-10-20
DK170821B1 (da) 1996-01-29
IL87468A (en) 1992-12-01
KR890003740A (ko) 1989-04-17
AU2107688A (en) 1989-03-02
JP2716740B2 (ja) 1998-02-18
ES2061576T3 (es) 1994-12-16
AU618549B2 (en) 1992-01-02
DK478788A (da) 1989-03-01
EP0304941B1 (de) 1994-02-02
DE3887598D1 (de) 1994-03-17
KR970011297B1 (ko) 1997-07-09
FI883961A0 (fi) 1988-08-26
YU161688A (en) 1990-10-31
HUT47564A (en) 1989-03-28
HK74494A (en) 1994-08-05
FI883961A (fi) 1989-03-01
MY104061A (en) 1993-11-30
NO883805D0 (no) 1988-08-25
OA08908A (en) 1989-10-31
DK478788D0 (da) 1988-08-26
YU46962B (sh) 1994-09-09
IE882528L (en) 1989-02-28
ZA886082B (en) 1989-04-26

Similar Documents

Publication Publication Date Title
ATE101147T1 (de) Pharmazeutisch verwendbare polymorphe modifikation von buspiron.
ES2132284T3 (es) Derivados de carbamato de 2-(piperidin-4-il, piridin-4-il y tetrahidropiridin-4-il)-benzofurano-7, su preparacion y su uso como inhibidores de acetilcolinesterasa.
ES2100851T3 (es) Acidos quinolincarboxilicos sustituidos.
SE8305467D0 (sv) 1,4-dihydropyridinderivat
ATE79257T1 (de) Verwendung von tetrahydrobenz(c,d>indol-6carboxamiden zur herstellung von arzneimitteln zur behandlung von angstzustaenden.
PT87005A (pt) Process for preparing n-phenethylaminoalkyl-benzamide anti-arrhythmic agents
FI893682A (fi) Menetelmä terapeuttisesti käyttökelpoisten 1,2,5-ditiatsosiinijohdannaisten valmistamiseksi
ATE113044T1 (de) Verfahren zur umwandlung des niedrigschmelzenden polymorphs von buspirone hydrochlorid in das höherschmelzende.
ES2053707T3 (es) Procedimiento para la preparacion de amidas de acidos 3,3-diaril-acrilicos.
DE69710526D1 (de) Verwendung von 3-(4-Hexyloxy-1,2,5-Thiadiazol-3-yl)-1,2,5,6-Tetrahydro-1-Methylpyridin (Xanomelin) zur Behandlung von bipolaren Störungen
ES557207A0 (es) Un procedimiento para preparar benzo(c)-1,5-naftiridinas
TH11174EX (th) อนุพันธ์ของพิเพอดิลอกซิ-ไอซอกซาโซล,การเตรียมสารเหล่านั้นและการใช้ในการรักษา

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
REN Ceased due to non-payment of the annual fee